Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $36.40 Consensus Price Target from Brokerages

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Get Free Report) has received a consensus rating of “Hold” from the five research firms that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year price target […]

Leave a Reply

Your email address will not be published.

Previous post UK firms cutting staff at fastest pace since February as economic pressures mount
Next post Fonix Mobile (LON:FNX) Receives “Buy” Rating from Canaccord Genuity Group